|Benefit-Cost Summary Statistics Per Participant|
|Taxpayers||$1,685||Benefits minus costs||$3,506|
|Participants||$2,062||Benefit to cost ratio||$1.72|
|Others||$863||Chance the program will produce|
|Indirect||$3,764||benefits greater than the costs||76 %|
|Net program cost||($4,867)|
|Benefits minus cost||$3,506|
|Meta-Analysis of Program Effects|
|Outcomes measured||Treatment age||No. of effect sizes||Treatment N||Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis||Unadjusted effect size (random effects model)|
|First time ES is estimated||Second time ES is estimated|
Opioid use disorder
Clinical diagnosis of opioid use disorder or symptoms on a validated scale.
Emergency department visits^^
Whether someone visited the emergency department, or the number of times they visited the emergency department.
Mental health symptoms (such as symptoms of psychosis) in individuals with serious mental illness, measured on a validated scale.
|Detailed Monetary Benefit Estimates Per Participant|
|Affected outcome:||Resulting benefits:1||Benefits accrue to:|
|Opioid use disorder||Criminal justice system||$0||$0||$1||$0||$1|
|Labor market earnings associated with opioid drug abuse or dependence||$563||$1,324||$0||($282)||$1,605|
|Health care associated with opioid drug abuse or dependence||$860||$123||$862||$430||$2,275|
|Mortality associated with opioids||$262||$615||$0||$6,049||$6,926|
|Program cost||Adjustment for deadweight cost of program||$0||$0||$0||($2,434)||($2,434)|
|Detailed Annual Cost Estimates Per Participant|
|Annual cost||Year dollars||Summary|
|Program costs||$4,431||2012||Present value of net program costs (in 2018 dollars)||($4,867)|
|Comparison costs||$0||2012||Cost range (+ or -)||30 %|
Benefits Minus Costs
Benefits by Perspective
Taxpayer Benefits by Source of Value
|Benefits Minus Costs Over Time (Cumulative Discounted Dollars)|
|The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.|
Cropsey, K.L., Lane, P.S., Hale, G.J., Jackson, D.O., Clark, C.B., Ingersoll, K.S., Islam, M.A., Stitzer, M.L. (2011). Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drug and Alcohol Dependence, 119(3), 172-178.
Fudala, P.J., Bridge, T.P., Herbert, S., Williford, W.O., Chiang, C.N., Jones, K., . . . Tusel, D. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. The New England Journal of Medicine, 349(10), 949-958.
Kakko, J., Svanborg, K.D., Kreek, M.J., & Heilig, M. (2003). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet, 361(9358), 662-668.
Krook, A.L., Brørs, O., Dahlberg, J., Grouff, K., Magnus, P., Røysamb, E., & Waal, H. (2002). A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction, 97(5), 533-542.
Liebschutz, J.M., Crooks, D., Herman, D., Anderson, B., Tsui, J., Meshesha, L.Z., Dossabhoy, S., Stein, M. (2014). Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. Jama Internal Medicine, 174(8), 1369-76.
Ling, W., Charuvastra, C., Collins, J.F., Batki, S., Brown, L.S., Kintaudi, P., . . . Segal, D. (1998). Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction, 93(4), 475.
Lucas, G. M., Chaudhry, A., Hsu, J., Woodson, T., Lau, B., Olsen, Y., Keruly, J. C., ... Moore, R. D. (2010). Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Annals of Internal Medicine, 152, 11, 704-711.
Rosenthal, R.N., Ling, W., Casadonte, P., Vocci, F., Bailey, G.L., Kampman, K., ... & Beebe, K.L. (2013). Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction, 108(12), 2141-2149.